Compliance with allergen immunotherapy and factors affecting compliance among patients with respiratory allergies
Affiliations
Affiliations
- Al-Rashid Allergy Center , Ministry of Health , Kuwait City , Kuwait.
- Department of Microbiology , Faculty of Medicine, Kuwait University , Kuwait City , Kuwait.
- Department of Pediatrics , Faculty of Medicine, Kuwait University , Kuwait City , Kuwait.
- Allergy and Clinical Immunology Unit, Department of Pediatrics , Al-Sabah Hospital , Kuwait City , Kuwait.
Abstract
Allergen-specific immunotherapy (AIT) is safe and effective for the treatment of allergic rhinitis and allergic asthma. However, patient non-compliance is a major barrier to achieving optimal outcomes Objective: To determine the level of compliance among patients using AIT and to identify factors associated with non-compliance Methods: A retrospective analysis using questionnaires was conducted to study compliance among 236 patients with allergic rhinitis with or without asthma who began AIT in 2009 or 2010 Results: The compliance rates at 3 y were 58.7% among patients on subcutaneous immunotherapy (SCIT) and 11.6% among those on sublingual immunotherapy (SLIT). The mean durations of treatment with SCIT and SLIT were 31 (+/-18.3) and 15.9 (+/-14.7) months, respectively. The most common causes of non-compliance among patients on SCIT were the frequency of injections (82.2%), the duration of treatment (70.9%), and commuting to the Allergy Center (67.7%). Reasons for non-compliance among patients on SLIT were related to inconvenience (43.4%), improvement without treatment (30.2%) and perception of poor efficacy (25.0%) Conclusion: Compliance with AIT is low, but at 3 years, it was higher among patients on SCIT than among patients on SLIT. Reasons for non-compliance include difficulty adjusting to treatment protocols and a perception that the efficacy is low. Patient education regarding the treatment course and the slow effect, as well as the need for close follow up to effectively prevent and treat adverse reactions, are important factors for improving compliance and treatment outcomes.
Keywords: adherence; allergen-specific immunotherapy; compliance; subcutaneous; sublingual.
Similar articles
Manzotti G, Riario-Sforza GG, Dimatteo M, Scolari C, Makri E, Incorvaia C.Eur Ann Allergy Clin Immunol. 2016 Nov;48(6):224-227.PMID: 27852426 Clinical Trial.
Compliance in subcutaneous and sublingual allergen immunotherapy: A nationwide study.
Borg M, Løkke A, Hilberg O.Respir Med. 2020 Aug-Sep;170:106039. doi: 10.1016/j.rmed.2020.106039. Epub 2020 May 30.PMID: 32843170
Kiel MA, Röder E, Gerth van Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP.J Allergy Clin Immunol. 2013 Aug;132(2):353-60.e2. doi: 10.1016/j.jaci.2013.03.013. Epub 2013 May 4.PMID: 23651609
Calderon MA, Casale TB, Nelson HS, Demoly P.J Allergy Clin Immunol. 2013 Dec;132(6):1322-36. doi: 10.1016/j.jaci.2013.09.004. Epub 2013 Oct 18.PMID: 24139829 Review.
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma.
Passalacqua G, Canonica GW, Bagnasco D.Curr Allergy Asthma Rep. 2016 Nov;16(12):88. doi: 10.1007/s11882-016-0666-x.PMID: 27957697 Review.
Cited by
Huang RR, Zhu XH, Wang JL.Zhongguo Dang Dai Er Ke Za Zhi. 2022 Dec 15;24(12):1371-1375. doi: 10.7499/j.issn.1008-8830.2207131.PMID: 36544421 Free PMC article. Chinese.
Adherence in allergen immunotherapy: Current situation and future implications.
Gehrt F, Xu Q, Baiardini I, Canonica GW, Pfaar O.Allergol Select. 2022 Nov 21;6:276-284. doi: 10.5414/ALX02318E. eCollection 2022.PMID: 36457724 Free PMC article. Review.
Mohana Karthikeyan S, Nikisha GN.Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):1169-1177. doi: 10.1007/s12070-020-02249-2. Epub 2020 Oct 31.PMID: 36452711
Mormile I, Granata F, Detoraki A, Pacella D, Della Casa F, De Rosa F, Romano A, de Paulis A, Rossi FW.Biomedicines. 2022 Apr 22;10(5):971. doi: 10.3390/biomedicines10050971.PMID: 35625708 Free PMC article.
Shardlow E, Exley C.RSC Adv. 2019 Aug 7;9(42):24505-24518. doi: 10.1039/c9ra03831k. eCollection 2019 Aug 2.PMID: 35527856 Free PMC article.